MIM
DXCM icon

MetLife Investment Management’s DexCom DXCM Stock Holding History

MetLife Investment Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96M Sell
103,307
-4,367
-4% -$291K 0.03% 505
2026
Q1 		$6.76M Sell
107,674
-4,688
-4% -$326K 0.03% 496
2025
Q4 		$7.46M Sell
112,362
-3,430
-3% -$222K 0.04% 455
2025
Q3 		$7.79M Sell
115,792
-1,895
-2% -$150K 0.04% 442
2025
Q2 		$10.3M Sell
117,687
-761
-0.6% -$59.6K 0.06% 307
2025
Q1 		$8.09M Sell
118,448
-2,119
-2% -$173K 0.04% 410
2024
Q4 		$9.38M Sell
120,567
-1,844
-2% -$137K 0.05% 278
2024
Q3 		$8.21M Sell
122,411
-1,967
-2% -$162K 0.05% 310
2024
Q2 		$14.1M Buy
124,378
+18,102
+17% +$2.29M 0.08% 174
2024
Q1 		$14.7M Sell
106,276
-3,456
-3% -$434K 0.1% 160
2023
Q4 		$13.6M Sell
109,732
-2,291
-2% -$234K 0.1% 161
2023
Q3 		$10.5M Sell
112,023
-2,454
-2% -$277K 0.08% 193
2023
Q2 		$14.7M Sell
114,477
-597
-0.5% -$72.2K 0.11% 143
2023
Q1 		$13.4M Sell
115,074
-1,120
-1% -$125K 0.1% 156
2022
Q4 		$13.2M Sell
116,194
-4,238
-4% -$465K 0.1% 157
2022
Q3 		$9.7M Sell
120,432
-1,321
-1% -$112K 0.08% 202
2022
Q2 		$9.07M Sell
121,753
-939
-0.8% -$85.7K 0.07% 221
2022
Q1 		$15.7M Buy
122,692
+37,032
+43% +$4.05M 0.1% 156
2021
Q4 		$11.5M Sell
85,660
-1,752
-2% -$252K 0.09% 167
2021
Q3 		$12M Sell
87,412
-2,272
-3% -$287K 0.11% 151
2021
Q2 		$9.57M Sell
89,684
-1,992
-2% -$191K 0.08% 195
2021
Q1 		$8.24M Sell
91,676
-1,608
-2% -$151K 0.08% 229
2020
Q4 		$8.62M Sell
93,284
-3,816
-4% -$341K 0.08% 197
2020
Q3 		$10M Buy
97,100
+536
+0.6% +$56K 0.11% 159
2020
Q2 		$9.79M Buy
+96,564
New +$8.64M 0.11% 160
2019
Q2 		– Sell
-1,440
Closed -$42.6K – 2472
2019
Q1 		$42.6K Buy
1,440
+964
+203% +$33.9K ﹤0.01% 2361
2018
Q4 		$14.3K Sell
476
-4
-0.8% -$127 ﹤0.01% 2353
2018
Q3 		$17.2K Buy
+480
New +$14.9K ﹤0.01% 2395

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MetLife Investment Management's DXCM Position: Q2 2026 in Review

MetLife Investment Management reduced its DexCom (DXCM) stake by 4.1% in Q2 2026, selling an estimated $291K and leaving 103,307 shares worth $6.96M. The position accounts for 0.03% of the portfolio, ranked #505.

MetLife Investment Management first reported a position in DXCM in Q3 2018 and has held it in 28 quarters since. The position peaked at $15.7M in Q1 2022. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • MetLife Investment Management held 103,307 shares of DexCom worth $6.96M as of Q2 2026.
  • MetLife Investment Management sold 4,367 DexCom shares in Q2 2026, an estimated $291K.
  • DexCom made up 0.03% of MetLife Investment Management's portfolio in Q2 2026, its #505 holding.
  • MetLife Investment Management first reported a position in DexCom in Q3 2018 and has held it in 28 quarters since.
  • MetLife Investment Management's DexCom position peaked at $15.7M in Q1 2022.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.